Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial-Reference-Cited by-同舟云学术

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Published:2015-11 Issue:15 Volume:16 Page:1473-1482
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Motzer Robert J,Hutson Thomas E,Glen Hilary,Michaelson M Dror,Molina Ana,Eisen Timothy,Jassem Jacek,Zolnierek Jakub,Maroto Jose Pablo,Mellado Begoña,Melichar Bohuslav,Tomasek Jiri,Kremer Alton,Kim Han-Joo,Wood Karen,Dutcus Corina,Larkin James

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Clinical practice guidelines in oncology, version 3: kidney cancer,2015

2. EAU guidelines on renal cell carcinoma: 2014 update;Ljungberg;Eur Urol,2015

3. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase;Matsui;Clin Cancer Res,2008

4. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition;Matsui;Int J Cancer,2008

5. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models;Okamoto;Cancer Lett,2013

Cited by 802 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07

2. Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database;British Journal of Clinical Pharmacology;2024-09-02

3. The treatment of metastatic renal cell carcinoma;Deutsches Ärzteblatt international;2024-08-23

4. Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology;Current Oncology;2024-08-22

5. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma;New England Journal of Medicine;2024-08-22